Results 31 to 40 of about 505,510 (298)

Characterization of respiratory dendritic cells from equine lung tissues

BMC Veterinary Research, 2017
Background Dendritic cells (DCs) are professional antigen-presenting cells that have multiple subpopulations with different phenotypes and immune functions. Previous research demonstrated that DCs have strong potential for anti-viral defense in the host.
Yao Lee, Matti Kiupel, Gisela Soboll Hussey   +2 more
doaj   +1 more source

Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. [PDF]

, 1993
We have generated transgenic mice that express the immunoglobulin (Ig)M heavy chain and kappa light chain genes coding for a human IgM rheumatoid factor (RF), Les.
Carson, DA, Chen, PP, Jirik, FR, Kipps, TJ, Roudier, J, Tighe, H, Tucker, R   +6 more
core   +2 more sources

Liver antigen-presenting cells

Journal of Hepatology, 2011
The liver is an organ in which several major pathogens evade immune clearance and achieve chronicity. How do they do it? Recent research has documented multiple mechanisms by which immune responses in the liver are biased towards tolerance. In this review, the induction of local, intrahepatic tolerance is explored from the perspective of antigen ...
openaire   +2 more sources

The B subunit of Escherichia coli heat-labile toxin alters the development and antigen-presenting capacity of dendritic cells [PDF]

, 2015
Escherichia coli’s heat-labile enterotoxin (Etx) and its non-toxic B subunit (EtxB) have been characterized as adjuvants capable of enhancing T cell responses to co-administered antigen.
Griffiths, Kristin L., Hirst, Timothy R., Ji, Jing, Milburn, Peter J., O'Neill, Helen C.   +4 more
core   +1 more source

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]

, 2001
The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A, Clark, EA, Daemen, K, Hayden-Ledbetter, M, Irgang, M, Korner, I, Ledbetter, JA, Pezzutto, A, Richter, G, Westermann, J   +9 more
core  

Collective Classification of Textual Documents by Guided Self-Organization in T-Cell Cross-Regulation Dynamics

, 2011
We present and study an agent-based model of T-Cell cross-regulation in the adaptive immune system, which we apply to binary classification. Our method expands an existing analytical model of T-cell cross-regulation (Carneiro et al. in Immunol Rev 216(1):
Abi-Haidar, Alaa, Rocha, Luis M.
core   +1 more source

To respond or not to respond - a personal perspective of intestinal tolerance [PDF]

, 2018
For many years, the intestine was one of the poor relations of the immunology world, being a realm inhabited mostly by specialists and those interested in unusual phenomena.
A Besredka, A Goubier, A Iwasaki, A Konrad, A Limmer, A Mortha, A Vaillant, AJ MacPherson, Allan McI. Mowat, AM Mowat, B Cassani, B Dubois, B Jabri, B Johansson-Lindbom, C Asseman, C Berlin, C Siewert, C Varol, CC Bain, CC Bain, CL Scott, CL Scott, CM Sun, CR Mackay, CR Stokes, D Esterhazy, D Fina, D Mucida, D Sichien, DP McGovern, DS Shouval, E Jaensson, E Jaensson-Gyllenback, E Mazzini, E Zigmond, EJ Kunkel, EM Nilsen, EM Nilsen, F Broere, F Ginhoux, F Hauet-Broere, F Powrie, FG Chirdo, G Lack, G Matteoli, G Mayrhofer, G Monteleone, GG MacPherson, H Arentz-Hanson, H Fukaura, H Tlaskalova, HG Wells, HL Klaasen, HL Weiner, HL Weiner, I Vicente-Suarez, ID Iliev, II Ivanov, J Farache, J Farache, JA Mattingly, JA Mattingly, JB Sun, JF Heremans, JH Niess, JL Coombes, JL Gowans, JL Viney, JM Blander, JP Hugot, JR Battisto, JR McDole, K Atarashi, K Atarashi, K Lahl, K Nagatani, K Takeda, KG McDonald, KM Luda, KM Smith, KP Zimmer, KS Kim, L Maiuri, L Maiuri, L Saurer, LA Hanson, LA Reynolds, LA Waaij van der, LM Sollid, M Boucard-Jourdin, M Butler, M Chieppa, M Karlsson, M Murai, M Rescigno, M Rimoldi, M Tsuji, M Yoshida, MH Jang, MH Jang, MO Li, MR Hepworth, MR Karlsson, MW Chase, N Korneychuk, N Satoh-Takayama, N Sudo, O Schulz, P Brandtzaeg, P Morrissey, PA Crabbe, PB Carter, PM Smith, R Bouziat, R Kuhn, R Zeng, R Zeng, RE Araya, RL Owen, RW DePaolo, S Hue, S Husby, S Husby, S Kawamoto, S Strobel, S Strobel, S Veenbergen, S Wilks, SI Hammerschmidt, SK Mazmanian, SV Kim, T Joeris, T Worbs, TB Tomasi Jr, TL Denning, U Hadis, V Cerovic, V Gaboriau-Routhiau, Y Chen, Y Cong, Y Ogura, ZM Falchuk, Ø Molberg   +142 more
core   +1 more source

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul, Jatuporn Sujjitjoon, Pa‐thai Yenchitsomanus, Kridtin Jarutatsanangkoon, Ng Wei Loon, Kleebsabai Sanpakit, Jassada Buaboonnam, Chayamon Takpradit, Pornpimon Yuti, Nunghathai Sawasdee, Piriya Luangwattananun, Siripakorn Sangkitporn, Arnan Limmahachai, La‐ongsri Atchaneeyasakul   +13 more
wiley   +1 more source

Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens

Vaccines, 2019
The preferred product characteristics (for chemistry, control, and manufacture), in addition to safety and efficacy, are quintessential requirements for any successful therapeutic.
Cristina Poveda, Amadeo B. Biter, Maria Elena Bottazzi, Ulrich Strych   +3 more
doaj   +1 more source

Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle, Kiersten Ricci, Kelly Blache, Rebecca A. Marsh, Adrienne M. Hammill, Elissa Engel   +5 more
wiley   +1 more source